Screener
Moderna MRNA Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Moderna in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Moderna’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001682852-26-000060
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.0001; 162 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued or outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, par value $0.0001; 1,600 shares authorized as of March 31, 2026 and December 31, 2025; 397 and 394 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
| Additional paid-in capital | 1,503 | 1,382 |
| Accumulated other comprehensive income | 25 | 45 |
| Retained earnings | 5,880 | 7,223 |
| Total stockholders’ equity | 7,408 | 8,650 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Moderna's common stock, par value (in dollars per share)?
- Moderna (MRNA) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
- How has Moderna's common stock, par value (in dollars per share) changed year-over-year?
- Moderna's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Moderna's common stock, par value (in dollars per share)?
- Over 5 years (2020 to 2025), Moderna's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
Ask your AI about Moderna's common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude